Article Sidebar

PDF
Date Published: 25/12/2023
Online Published: 25/12/2023
Abstract Views: 155
Views PDF: 80
DOI: https://doi.org/10.58490/ctump.2023i69.1943
Issue
No. 69 (2023)
Section
Article
How to Cite
Le , H. P., & Nguyen , H. Q. (2023). RESPONSE OF LOCALLY ADVANCED LUMINAL A BREAST CANCER TO NEOADJUVANT CHEMOTHERAPY. Cantho Journal of Medicine and Pharmacy, 69, 200-206. https://doi.org/10.58490/ctump.2023i69.1943

RESPONSE OF LOCALLY ADVANCED LUMINAL A BREAST CANCER TO NEOADJUVANT CHEMOTHERAPY

Hoang Phuc Le 1,, Hoang Quy Nguyen 2
1 Can Tho University of Medicine and Pharmacy
2 University of Medicine and Pharmacy at Ho Chi Minh City

Main Article Content

Abstract

Background: The response of neoadjuvant chemotherapy  for patients with locally advanced luminal A breast cancer is unclear. Objectives: To determine the efficicacy of NAC and the predictive factors of a better response in patients with locally advanced luminal A breast cancer.  Materials and methods: A case series study of  41 patients with locally advanced luminal A breast cancer who were treated with neoadjuvant chemotherapy from January 2016 to December 2018 at Ho Chi Minh Oncology Hospital. Results: Clinical overall response rate (ORR) is 90.2%, pathological complete response rate (pCR) is 5.0% . The patients who receive combined anthracycline with taxane regimens tend to achieve a better response. Conclusions:  Neoadjuvant chemotherapy  is  a resonable option for locally advanced luminal A breast cancer since it provides a potential benefit of reduction in tumor extent. The addition of  taxane to an anthracycline-based regimen improves the clinical response rate.

Article Details

Keywords

breast cancer, locally advanced, luminal A, neoadjuvant chemotherapy

References

1. Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020:
GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. 2021; 71(3):209-249. doi:10.3322/caac.21660.
2. Trịnh Lê Huy, Thân Văn Thịnh. Nhận xét kết quả hóa trị bổ trợ phác đồ 4AC-4T kết hợp Anastrozole cho bệnh nhân ung thư vú ER dương tính/Her2 âm tính giai đoạn II-III. Tạp Chí Khoa học Và Công nghệ Việt Nam. 2022; 64(2):10-13. https://doi.org/10.31276/VJST.64(2).10-13.
3. Phạm Hoàng Quân. Kết quả điều trụ ung thư vú phân nhóm sinh học luminal A. Luận Văn Bác Sĩ Nội Trú. Đại Học Y Dược TP HCM; 2018.
4. Võ Xuân Bảo. Kết quả điều trị ung thư vú giai đoạn tiến triển tại chỗ, tại vùng thuộc phân nhóm tam âm. Luận văn thạc sĩ y học. Đại Học Y Dược TPHCM; 2020.
5. Collins PM, Brennan MJ, Elliott JA, et al. Neoadjuvant chemotherapy for luminal a breast cancer: Factors predictive of histopathologic response and oncologic outcome. American journal of surgery. 2021; 222(2):368-376. doi:10.1016/j.amjsurg.2020.11.053.
6. Chen S, Liu Y, Ouyang QW, Huang L, Luo RC, Shao ZM. Clinical and pathological response to neoadjuvant chemotherapy based on primary tumor reduction is correlated to survival in hormone receptor-positive but not hormone receptor-negative locally advanced breast cancer. Annals of surgical oncology. 2015; 22(1):32-9. doi:10.1245/s10434-014-3894-0.
7. Boughey JC, McCall LM, Ballman KV, et al. Tumor biology correlates with rates of breastconserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial. Annals of surgery. 2014; 260(4):608-14; discussion 614-6. doi:10.1097/sla.0000000000000924.
8. Nguyễn Thị Phương Thảo, Nguyễn Diệu Linh, Phạm Cẩm Phương. Kết quả hóa trị bổ trợ trước phác đồ 4AC-4T ở bệnh nhân ung thư vú giai đoạn tiến triển tại chỗ. Tạp Chí Y học Việt Nam. 2021; 503(2):205-209. doi: https://doi.org/10.51298/vmj.v503i2.802.
9. Nguyễn Hoàng Gia, Lê Thu Hà, Hán Thị Bích Hợp. Đánh giá kết quả hóa trị bổ trợ trước phác đồ 4AC-4T liều mau trên bệnh nhân ung thư vú giai đoạn III. Tạp chí ung thư học Việt Nam. 2021; 503(2):393-400.
10. Charfare H, Limongelli S, Purushotham AD. Neoadjuvant chemotherapy in breast cancer. The British journal of surgery. 2005; 92(1):14-23. doi:10.1002/bjs.4840.
11. Prat A, Fan C, Fernández A, et al. Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy. BMC medicine. 2015; 13(303. doi:10.1186/s12916-015-0540-z.
12. Phan Thị Hồng Đức, Lê Thanh Huy. Sống còn ung thư vú còn mổ được có hóa trị tân hỗ trợ. Tạp chí ung thư học Việt Nam. 2019; 4:199-204.
13. Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006; 24(13):2019-27.
doi:10.1200/jco.2005.04.1665.
14. Evans TR, Yellowlees A, Foster E, et al. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005; 23(13):2988-95. doi:10.1200/jco.2005.06.156.